Marzario Barbara, Cino Daniela, Colantonio Sophia
Division of Dermatology, Department of Medicine, University of Ottawa, ON, Canada.
The Ottawa Hospital, ON, Canada.
SAGE Open Med Case Rep. 2025 May 24;13:2050313X251341518. doi: 10.1177/2050313X251341518. eCollection 2025.
This case report describes, to our knowledge, the first known successful treatment of airborne allergic contact dermatitis to sesquiterpene lactone with upadacitinib in an adult patient. Recurrent summertime photodistributed eczematous eruptions should raise suspicion for airborne allergic contact dermatitis to sesquiterpene lactone, and positive patch test results to sesquiterpene lactone and Compositae in these patients should be considered highly relevant. In addition to allergen avoidance, treatment with systemic Janus kinase inhibitors can induce allergic contact dermatitis remission. Our patient did not respond to allergen avoidance or topical corticosteroids; however, he achieved almost complete resolution of his allergic contact dermatitis with a 6-week course of upadacitinib, a Janus kinase 1 inhibitor.
据我们所知,本病例报告描述了首例在成年患者中使用乌帕替尼成功治疗对倍半萜内酯的空气传播性过敏性接触性皮炎的案例。反复出现的夏季光分布性湿疹样皮疹应引起对倍半萜内酯空气传播性过敏性接触性皮炎的怀疑,这些患者对倍半萜内酯和菊科植物的斑贴试验阳性结果应被视为高度相关。除了避免接触过敏原外,使用系统性 Janus 激酶抑制剂进行治疗可诱导过敏性接触性皮炎缓解。我们的患者对避免接触过敏原或外用糖皮质激素均无反应;然而,他通过服用 Janus 激酶 1 抑制剂乌帕替尼进行为期 6 周的治疗,过敏性接触性皮炎几乎完全消退。